Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (August 2024)
15 slides from Enveric Biosciences's investor presentation, Aug 22, 2024
Slide 1: Next Generation Mental Health - Corporate Presentation Q3 2024
fl Nasdaq:ENvB — NW & Fes ; Mentol Health™ Mental Health™ OSC IBN CES CORPORATE PRESENTATION Q3 2024 Enveric .com
Slide 2: Disclaimer
Disclaimer No Offeror Solicitation This com munication is for inform ational purposes only and is not intended to and does not constitute an offerte sell orthe solicitation ofan offerto buy any securities ora solicitation ofany vote or approval. t does not constitute a p ospectts oF € prospectus equ
Slide 3: Slide 3
Slide 4: Significant Global Health Issues: Depression, Anxiety & PTSD
Significant Global Health Issues: Depression, Anxiety & PTSD 65 million in the US ey) 40% billion globally Experience a neuropsychiatric First line SSRI treatm ents work disorder at some time in their lives for less than half of patients Souree Source Recent Discovery: Mentalhealth disorders are ass
Slide 5: Neuroplastogens
Neuroplastogens: Prefrontal Cortex Healthy Brain _: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top -Down control of the amygdala. This modulates the fight — -or-flight thoughts and emotions that originate in the amygdala Neuropsychiatric Illness: Reduced neural connection
Slide 6: Psychedelic Neuroplastogen Drawbacks
Psychedelic Neuroplastogen Drawbacks: + Current neuroplastogens in clinical trials cause hallucinations in the patient + Require 8 hrs in-clinic treatment with two healthcare providers present, plus pre and post treatment counselling + Require psychotherapy as part of the treatment paradigm + Expens
Slide 7: EB-003: Non-Hallucinogenic Neuroplastogen Discovered in 1,000+ Molecule Library
EB-003: Non -Hallucinogenic r 7 on a oS" Neuroplastogen Discovered in N af 1,000+ Molecule Library NH, N * Integrated synthetic biology and Rr ij chemistry to create new library : * Designed molecules based on natural serotonin receptor ligands ¢ Screened 1,000+ molecules for optimal drug candidate
Slide 8: EB-003: A New Treatment Standard
EB-003: A New Treatment Standard Psychedelic SSRI & SNRI Neuroplastoeens EB-003 Immediate efficacy VY v Low side effects VY No sexual dysfunction VY v Does not cause weight gain VY VY Treatment in-clinic not required Vv Vv Large patient population VY VY Induces neuroplasticity in brain v Vv f4 wasda
Slide 9: EB-003: Development Underway
EB-003: Development Underway Synopsis of Target Benefits * Reduced hallucination profile, treatm ent in clinic not required * Lower side effects + Rapid acting * Orally bioavailable + Intended to be prescribed for regular maintenance and taken at times and in settings convenient to patient 1 1 DITIO
Slide 10: Market Potential
Market Potential: Redefining the Treatment Landscape for Mental Health Disorders Current SSRI/SNRI Market: Global market driven by the rising prevalence of Anxiety, Depression, and PTSD ( y of patients experience J inadequate relief Side Effects & Delayed Onset SSRIs/SNRIs take 4-6 weeks to work, wi
Slide 11: Additional Assets
Additional Assets Leveraged from Discovery Platform * Portfolio of 1,000+ novel drug candidates * 23 issued patents & 60 pending patent applications * Numerous distinct assets available for partnering or out - licensing * Multiple future revenue streams possible yf y LiNasdaq :-ENVB
Slide 12: Partnering & Licensing
Partnering & Licensing Total Possible Micsionelbennents Royalty Rates Partner / Licensee Assets for Partnering Partner EB-003 Available EB-002 Available Assets for Out _-Licen: Licensee Topical Product for Radiation a Tiered 7 . . . Dermatitis $61 Million 25% - 10% License Agreement with Aries Scien
Slide 13: Management
Management Management Team Joseph Tucker, Ph.D. CEO & Director Kevin Coveney, CPA CFO Peter Facchini , Ph.D. CIO Jillian Hagel, Ph.D. VP Innovation Board of Directors Michael D. Webb Board Chair George Kegler Director, Chair of the Audit Committee Frank Pasqualone Director, Chair of the Compensation
Slide 14: Potential First in Class Entrant to Large Mental Health Market
Potential First in Class Entrant to Large Mental Health Market EB-003: A Paradigm Shifting Drug Candidate + EB-003 is one of the leading neuroplastogen drug candidates + Anticipate human studies start by end of 2025 with value inflection data readouts during 2026 New Drug Class Market Opportunity +
Slide 15: Nasdaq: ENVB
Nasdaq :-ENVB Mental Health™ B ISOS _ € A-E NG VES Enveric.com
Enveric Biosciences — Investor Presentation (August 2024) on 6ix